Summary of Key Points Core Viewpoint - On January 27, 2026, Gongdong Medical (605369) closed at 19.54 yuan, down 1.31%, with a turnover rate of 1.06% and a trading volume of 23,400 shares, amounting to a transaction value of 45.47 million yuan [1]. Trading Information - On January 27, the net outflow of main funds was 579,500 yuan, accounting for 1.27% of the total transaction value [2]. - The net outflow of retail funds was 336,700 yuan, representing 0.74% of the total transaction value [1]. - Retail investors had a net inflow of 916,200 yuan, which is 2.01% of the total transaction value [1]. Company Announcements - Gongdong Medical announced a change in the signing accountants for the 2025 fiscal year, replacing the previous accountants with Yang Guoqing, who has been a certified public accountant since 2015 and has no penalties in the last three years [1][2]. - The change in accountants is not expected to adversely affect the company's financial statements or internal control audit for the 2025 fiscal year [1].

Trading Information Summary - On January 26, 2026, Gongdong Medical (605369) closed at 19.8 yuan, up 0.76%, with a turnover rate of 1.23% and a trading volume of 27,000 shares, amounting to a transaction value of 53.03 million yuan [1]. - On the same day, the net outflow of main funds was 402,000 yuan, accounting for 0.76% of the total transaction value; retail investors had a net inflow of 550,860 yuan, representing 10.39% of the total transaction value [2]. Company Announcement Summary - Gongdong Medical announced a change in the signing accountants for the 2025 fiscal year, replacing the previously appointed accountants with Yang Guoqing, who has been a certified public accountant in China since 2015 and has no penalties in the last three years [1][2]. - The change in accountants is not expected to adversely affect the company's financial statements or internal control audit for the 2025 fiscal year [1].

Group 1 - The core announcement is about the adjustment of the signing auditors for the 2025 financial statements and internal control audit of Gongdong Medical, changing from Ning Yifeng and Guo Senhao to Ning Yifeng and Yang Guoqing [2] - The change in auditors is due to internal work arrangement adjustments within Tianjian Accounting Firm and does not affect the audit work [2]

近日，公司收到天健会计师事务所（特殊普通合伙）出具的《关于变更签字 注册会计师的函》，现将具体情况公告如下： 一、本次签字会计师变更情况 证券代码：605369 证券简称：拱东医疗 公告编号：2026-002 浙江拱东医疗器械股份有限公司 关于变更签字会计师的公告 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 | | --- | | 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 浙江拱东医疗器械股份有限公司（以下简称"公司"）分别于 2025 年 4 月 21 日、2025 年 5 月 27 日召开公司第三届董事会第十四次会议、2024 年年度股 东大会，审议通过了《关于续聘会计师事务所的议案》，同意续聘天健会计师事 务所（特殊普通合伙）为公司 2025 年度审计机构。具体内容敬请查阅公司 2025 年 4 月 22 日披露于上海证券交易所网站（www.sse.com.cn）的《关于续聘会计 师事务所的公告》（公告编号：2025-011）。 浙江拱东医疗器械股份有限公司董事会 2026 年 1 月 27 日 天健会计师事务所（特殊普通合伙）作为公司 2025 年 ...

Core Viewpoint - Gongdong Medical expects a significant decrease in net profit for the fiscal year 2025, projecting a decline of 67.37% to 74.36% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 44 million to 56 million yuan for 2025 [1] - The net profit, excluding non-recurring gains and losses, is expected to be between 54 million and 66 million yuan, reflecting a year-on-year decrease of 60.75% to 67.89% [1] Subsidiary Performance - Trademark Plastics Inc. (TPI), a subsidiary of the company, reported revenue growth; however, its operating performance declined due to fluctuations in shipping prices [1] - The management has preliminarily assessed that the goodwill arising from the acquisition of TPI shows signs of impairment based on its current operating conditions [1] Investment and Losses - The company has increased its investment in Urumqi Jindongsheng Trading Co., Ltd., leading to control over this entity, which constitutes a merger under non-similar control [1] - This investment has resulted in an estimated non-operating loss of approximately 11 million yuan [1]

Group 1 - The core viewpoint of the article indicates that Gongdong Medical (605369) is experiencing a significant decline in expected profits for 2025, with projected net profit ranging from 44 million to 56 million yuan, representing a year-on-year decrease of 67.37% to 74.36% [3][4] - The company anticipates that the net profit after deducting non-recurring gains and losses will be between 54 million and 66 million yuan, reflecting a year-on-year decrease of 60.75% to 67.89% [3][4] - The decline in performance is attributed to factors such as goodwill impairment, decreased gross margin, and exchange rate fluctuations [3][4] Group 2 - As of January 23, 2026, Gongdong Medical's stock closed at 19.65 yuan, down 0.1%, with a turnover rate of 0.57% and a trading volume of 12,600 shares, amounting to a transaction value of 24.82 million yuan [1] - On January 23, the net outflow of main funds was 899,600 yuan, accounting for 3.62% of the total transaction value, while retail investors saw a net inflow of 1,177,200 yuan, representing 4.74% of the total transaction value [2][4]

Core Viewpoint - Gongdong Medical (605369) has announced a significant decline in expected profits for 2025, primarily due to goodwill impairment, decreased gross margins, and exchange rate fluctuations [1][3]. Performance Disclosure Highlights - Gongdong Medical expects a net profit attributable to shareholders for 2025 to be between 44 million and 56 million yuan, representing a year-on-year decrease of 67.37% to 74.36% [1][3]. - The company anticipates a net profit after deducting non-recurring gains and losses to be between 54 million and 66 million yuan, reflecting a year-on-year decline of 60.75% to 67.89% [1][3]. - The decline in performance is attributed to factors such as goodwill impairment, reduced gross margins, and fluctuations in exchange rates [1][3]. Company Announcement Summary - Gongdong Medical has released its annual performance forecast for 2025, detailing the expected ranges for net profit and net profit after non-recurring items [1][3].

Core Viewpoint - The company, Zhejiang Gongdong Medical Instrument Co., Ltd., anticipates a significant decline in net profit for the fiscal year 2025, projecting a decrease of 67.37% to 74.36% compared to the previous year [2][3]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 44 million to 56 million yuan for 2025, a decrease of 115.63 million to 127.63 million yuan from the previous year [2][3]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between 54 million to 66 million yuan, reflecting a reduction of 102.15 million to 114.15 million yuan year-on-year [3]. Group 2: Previous Year’s Performance - In the previous year, the total profit was 188.74 million yuan, with a net profit attributable to shareholders of the parent company at 171.63 million yuan, and a net profit excluding non-recurring gains and losses at 168.15 million yuan [4]. Group 3: Reasons for Performance Decline - The decline in performance is attributed to several factors: - **Goodwill Impairment**: The company anticipates a goodwill impairment of approximately 24 million to 30 million yuan due to the underperformance of its subsidiary, Trademark Plastics Inc., influenced by international trade policies and shipping cost fluctuations [4][5]. - **Decrease in Gross Margin**: The gross margin has declined due to slowed demand for certain products as a result of U.S. tariff policies and domestic medical procurement policies [5]. - **Exchange Rate Fluctuations**: Financial expenses related to exchange rate fluctuations have increased, contributing to the decline in net profit [6]. - **Non-operating Losses**: The company incurred an investment loss of approximately 11 million yuan due to additional investments in a controlled entity, impacting non-operating gains and losses [7].

Core Viewpoint - Gongdong Medical has announced a significant decline in its expected net profit for the year 2025, projecting a decrease of 67.37% to 74.36% compared to the previous year [2] Financial Performance - The company anticipates a net profit attributable to the parent company of between 44 million to 56 million yuan for the year 2025 [2] - This represents a reduction of 115.6328 million to 127.6328 million yuan compared to the same period last year [2]

Core Viewpoint - Gongdong Medical expects a net profit attributable to shareholders of 44 million to 56 million yuan for the full year of 2025, indicating a significant decline in profitability due to various operational challenges and external factors [1]. Group 1: Performance Forecast - The company anticipates a net profit of 44 million to 56 million yuan for 2025 [1]. - The decline in profit is attributed to goodwill impairment, decreased gross margins, and foreign exchange fluctuations [1]. Group 2: Business Impact Factors - Goodwill impairment is expected to be between 24 million to 30 million yuan due to the underperformance of its subsidiary, Trademark Plastics Inc. (TPI), influenced by international trade policies and shipping cost fluctuations [1]. - Gross margin has decreased due to slowed demand for certain products as a result of U.S. tariff policies and domestic medical procurement policies [1]. - Financial expenses have increased due to reduced foreign exchange gains, negatively impacting net profit [1]. Group 3: Financial Results - For the first three quarters of 2025, Gongdong Medical reported a main revenue of 845 million yuan, a year-on-year increase of 1.08% [2]. - The net profit attributable to shareholders for the same period was 71.96 million yuan, reflecting a 49.1% year-on-year decline [2]. - The gross margin for the period was reported at 30.13% [2].